Aleniglipron
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Gasherbrum Bio, Inc · Phase 1 · Status n/r · Enrollment 70
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet | n/r | n/r | n/r | n/r |
| Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 1): GSBR-1290/Placebo Tablet | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 2): GSBR-1290/Placebo Tablet | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule | n/r | n/r | n/r | n/r |
Not shown
- Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet: endpoint not reported
- Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule: endpoint not reported
- Part 2 (Cohort 1): GSBR-1290/Placebo Tablet: endpoint not reported
- Part 2 (Cohort 2): GSBR-1290/Placebo Tablet: endpoint not reported
- Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule: endpoint not reported